✨ New study finds Ozempic and Mounjaro protect the heart too
★ 88 전문 정보 ★
New research from the Technical University of Munich and Harvard Medical School reveals that popular GLP-1-based drugs, semaglutide (Ozempic) and tirzepatide (Mounjaro), not only promote weight loss but also significantly reduce the risk of heart attacks and strokes in patients with type 2 diabetes.
🎯 핵심 특징
✅ 고품질
검증된 정보만 제공
⚡ 빠른 업데이트
실시간 최신 정보
💎 상세 분석
전문가 수준 리뷰
📖 상세 정보
New research from the Technical University of Munich and Harvard Medical School reveals that popular GLP-1-based drugs, semaglutide (Ozempic) and tirzepatide (Mounjaro), not only promote weight loss but also significantly reduce the risk of heart attacks and strokes in patients with type 2 diabetes. Using real-world insurance data, the study found up to an 18% reduction in major cardiovascular events, confirming powerful heart-protective effects that appear to extend beyond weight control.